MTOR and non-small cell lung carcinoma: Cheng (Cheng et al., 2020a) and Raha (Raha et al., 2020) found that in colorectal cancer SW620, HCT116 cells and gastric cancer AGS cells, Naringin inhibits the proliferation of malignant tumor cells by inhibiting PI3K/Akt/mTOR signaling pathway and down regulating the phosphorylation level of mammalian Sirolimus target (mTOR); Similarly, in non-small cell lung cancer A549 and H460 cells (Zhongyuan et al., 2017), Naringin inhibits the proliferation and growth of NSCLC cancer lines by downregulating the expression of the downstream Signaling molecule p70S6K of mTOR1.